A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07047118
Recruiting
This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Urology Cancer Center PC, Omaha, Nebraska +4 locations
Conditions: Prostatic Cancer, Castration-Resistant
Register for Updates
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
NCT07104383
Recruiting
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Viking Clinical Site #2037, Birmingham, Alabama +111 locations
Conditions: Weight Loss
Register for Updates
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891
Recruiting
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
08/12/2025
Locations: Om Research LLC, Lancaster, California +89 locations
Conditions: Moderately to Severely Active Crohns Disease
Register for Updates
Store Safely: Rural Firearm Injury Prevention for Families
NCT06719713
Recruiting
The researchers are testing a firearm safety prevention strategy tailored for families with children who reside in a rural area. Researchers hypothesize that the intervention will lead to improvements in household firearm storage.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: University of Michigan, Ann Arbor, Michigan +1 locations
Conditions: Firearm Injury
Register for Updates
Examining the Circadian Timing Effects of the Hypotensive Response to Exercise
NCT07049783
Recruiting
The goal of this study is to learn how exercise timing affects blood pressure in adults with elevated or high blood pressure. Exercise can influence the body's natural 24-hour rhythms, including blood pressure patterns. A single exercise session can lower blood pressure for up to 24 hours, but it is not fully understood how the time-of-day for exercise affects this response. The main question this study aims to answer is: • When the same participant exercises at different times of day (morning,... Read More
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
08/12/2025
Locations: University of Delaware, Newark, Delaware
Conditions: Young Adults, Hypertension, Post-Exercise Hypotension, Circadian Rhythm
Register for Updates
Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease
NCT06824987
Recruiting
The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease (AMKD) who are homozygotes or compound heterozygotes for APOL1 high-risk genotypes (G1 and G2). The primary hypothesis to be evaluated is that AZD2373, compared with placebo, will result in a greater reduction in UACR as assessed by the relative change from Baseline in UACR at Week 30.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/12/2025
Locations: Research Site, Alabaster, Alabama +71 locations
Conditions: APOL1-Mediated Kidney Disease
Register for Updates
VIZ ACCESS HCM - Multi-Site Registry
NCT07103057
Recruiting
To describe the clinical, economic, and population characteristics of newly diagnosed, previously diagnosed, and suspected patients evaluated by Viz HCM. HCM is underdiagnosed in the community and AI algorithms have been developed as screening tools. However, it is not well understood how to best integrate AI screening tools and their potential impact.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Emory University, Atlanta, Georgia +2 locations
Conditions: Hypertrophic Cardiomyopathy
Register for Updates
Accelerated rTMS vs. Sham for Stroke Apathy
NCT07113067
Recruiting
Apathy is a common set of symptoms seen in many people following a stroke. Apathy occurs when a person has lost motivation, becomes withdrawn, and stops doing things that used to be important to them. Apathy has a large negative impact on a person's quality of life, and can also have a large impact the people who take care of them. There are currently no FDA-approved treatments to help with apathy, and other services like therapy may be difficult to access for people who have had a stroke. To ad... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/12/2025
Locations: Medical University of South Carolina Brain Stimulation Lab, Charleston, South Carolina
Conditions: Apathy, Stroke, Stroke Sequelae, Stroke/Brain Attack, Stroke/ Cerebrovascular Accident (Ischemic or Hemorrhagic), Motivation, Abulia
Register for Updates
Temporal Investigation of Multimodal Elements
NCT07107386
Recruiting
The TIME Study is a research project aiming to understand the body's natural rhythms. The goal is to see how daily and weekly changes in our bodies-from what's happening at a molecular level to data from wearable devices-are connected. What is the study about? This study is trying to create a detailed map of how a person's body changes over time. By looking at information from blood, urine, and other samples, as well as data from smartwatches and other devices, researchers want to learn how our... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
08/12/2025
Locations: Buck Institute, Novato, California
Conditions: Health
Register for Updates
VK2735 for Weight Management Phase 3
NCT07104500
Recruiting
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Viking Clinical Site #1037, Birmingham, Alabama +120 locations
Conditions: Weight Loss
Register for Updates
Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
NCT07131631
Recruiting
This is a multi-center, prospective, observational study designed to evaluate the impact of LV myocardial fibrosis extent assessed by CMR on LV reverse remodeling and clinical outcomes post TEER. The target sample will be up to 125 patients enrolled to achieve 100 evaluable at 6 months of follow-up. Enrollment will occur at up to eight centers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Minneapolis Heart Institute Foundation, Minneapolis, Minnesota +5 locations
Conditions: Heart Failure and Reduced Ejection Fraction, Functional Mitral Regurgitation
Register for Updates
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878
Recruiting
This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
08/12/2025
Locations: Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan, Dothan, Alabama +180 locations
Conditions: Moderately to Severely Active Crohns Disease
Register for Updates